CureChat is a digital health company specializing in AI-driven solutions for chronic disease management. Its flagship product, Dana, is an AI-powered diabetes assistant that provides free, personalized, and medically accurate support based on ADA guidelines. CureChat focuses on improving diabetes education and accessibility, particularly in emerging markets, while ensuring privacy and compliance with healthcare standards.
Cumulative Funding Raised Over Time ($)
Employees Over Time
CureChat Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Aug 9, 2024
www.robertplank.com
1144: Diabetes Management Reimagined: Exploring the Innovative Dana Chatbot with CureChat Ltd Founder Dr. Shimon Zilbershlag